TREA

88830833 - TRIVAIR

Follow

Information

  • Trademark
  • 88830833
  • Serial Number
    88830833
  • Filing Date
    March 11, 2020
    5 years ago
  • Transaction Date
    March 17, 2025
    8 months ago
  • Status Date
    March 16, 2025
    8 months ago
  • Location Date
    March 16, 2025
    8 months ago
  • Status Code
    653
  • Current Location
    TMO LAW OFFICE 122
    Employee Name
    ROTH, BENJAMIN
  • Attorney Docket Number
    003545.00074
    Attorney Name
    Darrell G. Mottley
    Law Office Assigned Location Code
    N40
  • Owners
Information
Mark Drawing Code
4
Mark Identification
TRIVAIR
Case File Statements
  • GS0051: Inhalers filled with pharmaceutical preparations for use in the treatment of respiratory diseases, disorders and infections; inhalers filled with pharmaceutical preparations for use in the treatment of asthma; inhalers filled with pharmaceutical preparations for use in the treatment of chronic obstructive pulmonary disease; inhalers filled with pharmaceutical preparations for use in the treatment of rhinitis; inhalers filled with pharmaceutical preparations for use in the treatment of sinus polyps; inhalers filled with pharmaceutical preparations for use in the treatment of viral airway infections; inhalers filled with pharmaceutical preparations for use in the treatment of multiple sclerosis; inhalers filled with pharmaceutical preparations for use in the treatment of depression; inhalers filled with pharmaceutical preparations for use in the treatment of epilepsy; inhalers filled with pharmaceutical preparations for use in the treatment of migraine; inhalers filled with pharmaceutical preparations for use in the treatment of Alzheimer's disease; inhalers filled with pharmaceutical preparations for use in the treatment of Parkinson's disease; inhalers filled with pharmaceutical preparations for use in the treatment of cerebrovascular accident or stroke; inhalers filled with pharmaceutical preparations for use in the treatment of traumatic brain injury; inhalers filled with pharmaceutical preparations for use in the treatment of cancer; inhalers filled with pharmaceutical preparations for use in the treatment of nausea; inhalers filled with pharmaceutical preparations for use in the treatment of post-traumatic stress disorder; inhalers filled with pharmaceutical preparations for use in the treatment of amyotrophic lateral sclerosis; inhalers filled with pharmaceutical preparations for use in the treatment of chronic pain; inhalers filled with pharmaceutical preparations for use in the treatment of insomnia; inhalers filled with pharmaceutical preparations for use in the relief of pain; inhalers filled with pharmaceutical preparations for use in the treatment of cough or sore throat; inhalers filled with pharmaceutical preparations for use in the treatment of candida infection; inhalers filled with pharmaceutical preparations for use in anti-fungal treatment; inhalers filled with pharmaceutical preparations for use in sedation; inhalers filled with pharmaceutical preparations for use in hormone replacement therapy; inhalers filled with pharmaceutical preparations for use in the treatment of psychosis; drug delivery devices, namely, breath actuated nasal delivery devices filled with pharmaceutical preparations for use in the treatment of respiratory diseases, disorders and infections; drug delivery devices, namely, breath actuated nasal delivery devices filled with pharmaceutical preparations for use in the treatment of asthma; drug delivery devices, namely, breath actuated nasal delivery devices filled with pharmaceutical preparations for use in the treatment of chronic obstructive pulmonary disease; drug delivery devices, namely, breath actuated nasal delivery devices filled with pharmaceutical preparations for use in the treatment of rhinitis; drug delivery devices, namely, breath actuated nasal delivery devices filled with pharmaceutical preparations for use in the treatment of sinus polyps; drug delivery devices, namely, breath actuated nasal delivery devices filled with pharmaceutical preparations for use in the treatment of viral airway infections; drug delivery devices, namely, breath actuated nasal delivery devices filled with pharmaceutical preparations for use in the treatment of multiple sclerosis; drug delivery devices, namely, breath actuated nasal delivery devices filled with pharmaceutical preparations for use in the treatment of depression; drug delivery devices, namely, breath actuated nasal delivery devices filled with pharmaceutical preparations for use in the treatment of epilepsy; drug delivery devices, namely, breath actuated nasal delivery devices filled with pharmaceutical preparations for use in the treatment of migraine; drug delivery devices, namely, breath actuated nasal delivery devices filled with pharmaceutical preparations for use in the treatment of Alzheimer's disease; drug delivery devices, namely, breath actuated nasal delivery devices filled with pharmaceutical preparations for use in the treatment of Parkinson's disease; drug delivery devices, namely, breath actuated nasal delivery devices filled with pharmaceutical preparations for use in the treatment of cerebrovascular accident or stroke; drug delivery devices, namely, breath actuated nasal delivery devices filled with pharmaceutical preparations for use in the treatment of traumatic brain injury; drug delivery devices, namely, breath actuated nasal delivery devices filled with pharmaceutical preparations for use in the treatment of cancer; drug delivery devices, namely, breath actuated nasal delivery devices filled with pharmaceutical preparations for use in the treatment of nausea; drug delivery devices, namely, breath actuated nasal delivery devices filled with pharmaceutical preparations for use in the treatment of post-traumatic stress disorder; drug delivery devices, namely, breath actuated nasal delivery devices filled with pharmaceutical preparations for use in the treatment of amyotrophic lateral sclerosis; drug delivery devices, namely, breath actuated nasal delivery devices filled with pharmaceutical preparations for use in the treatment of chronic pain; drug delivery devices, namely, breath actuated nasal delivery devices filled with pharmaceutical preparations for use in the treatment of insomnia; drug delivery devices, namely, breath actuated nasal delivery devices filled with pharmaceutical preparations for use in the relief of pain; drug delivery devices, namely, breath actuated nasal delivery devices filled with pharmaceutical preparations for use in the treatment of cough or sore throat; drug delivery devices, namely, breath actuated nasal delivery devices filled with pharmaceutical preparations for use in the treatment of candida infection; drug delivery devices, namely, breath actuated nasal delivery devices filled with pharmaceutical preparations for use in anti-fungal treatment; drug delivery devices, namely, breath actuated nasal delivery devices filled with pharmaceutical preparations for use in sedation; drug delivery devices, namely, breath actuated nasal delivery devices filled with pharmaceutical preparations for use in hormone replacement therapy; drug delivery devices, namely, breath actuated nasal delivery devices filled with pharmaceutical preparations for use in the treatment of psychosis; inhalers used to deliver therapeutic agents, namely, analgesics, sedatives, vaccines, anesthetics, insulin, antiemetics, antifungals, hormones, or antipsychotics; drug delivery devices, namely, breath actuated nasal delivery devices used to deliver therapeutic agents, namely, analgesics, sedatives, vaccines, anesthetics, insulin, antiemetics, antifungals, hormones, or antipsychotics; inhalers filled with analgesics, sedatives, vaccines, anesthetics, insulin, antiemetics, antifungals, hormones, respiratory therapeutic agents, or antipsychotics; drug delivery devices, namely, breath actuated nasal delivery devices filled with analgesics, sedatives, vaccines, anesthetics, insulin, antiemetics, antifungals, hormones, respiratory therapeutic agents, or antipsychotics; none of the foregoing containing cannabis or CBD
  • GS0101: Medical apparatus and instruments, namely, inhalers, sold empty, for therapeutic use; medical apparatus and instruments, namely, breath actuated nasal drug delivery devices, sold empty, for therapeutic use; none of the foregoing for use with cannabis or CBD
Case File Event Statements
  • 3/14/2020 - 5 years ago
    1 - NEW APPLICATION ENTERED Type: NWAP
  • 3/18/2020 - 5 years ago
    2 - NEW APPLICATION OFFICE SUPPLIED DATA ENTERED Type: NWOS
  • 6/2/2020 - 5 years ago
    3 - ASSIGNED TO EXAMINER Type: DOCK
  • 6/17/2020 - 5 years ago
    4 - ASSIGNED TO EXAMINER Type: DOCK
  • 9/14/2020 - 5 years ago
    5 - ASSIGNED TO EXAMINER Type: DOCK
  • 9/14/2020 - 5 years ago
    6 - NON-FINAL ACTION WRITTEN Type: CNRT
  • 9/14/2020 - 5 years ago
    7 - NON-FINAL ACTION E-MAILED Type: GNRT
  • 9/14/2020 - 5 years ago
    8 - NOTIFICATION OF NON-FINAL ACTION E-MAILED Type: GNRN
  • 1/5/2021 - 4 years ago
    9 - EXAMINERS AMENDMENT -WRITTEN Type: CNEA
  • 1/5/2021 - 4 years ago
    10 - EXAMINERS AMENDMENT E-MAILED Type: GNEA
  • 1/5/2021 - 4 years ago
    11 - NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED Type: GNEN
  • 1/5/2021 - 4 years ago
    12 - EXAMINER'S AMENDMENT ENTERED Type: XAEC
  • 1/8/2021 - 4 years ago
    13 - SUSPENSION LETTER WRITTEN Type: CNSL
  • 1/8/2021 - 4 years ago
    14 - LETTER OF SUSPENSION E-MAILED Type: GNSL
  • 1/8/2021 - 4 years ago
    15 - NOTIFICATION OF LETTER OF SUSPENSION E-MAILED Type: GNS3
  • 9/1/2021 - 4 years ago
    16 - SUSPENSION CHECKED - TO ATTORNEY FOR ACTION Type: RCCK
  • 10/5/2021 - 4 years ago
    17 - SUSPENSION INQUIRY WRITTEN Type: CNSI
  • 10/5/2021 - 4 years ago
    18 - INQUIRY TO SUSPENSION E-MAILED Type: GNSI
  • 10/5/2021 - 4 years ago
    19 - NOTIFICATION OF INQUIRY AS TO SUSPENSION E-MAILED Type: GNS2
  • 5/3/2022 - 3 years ago
    20 - ASSIGNED TO EXAMINER Type: DOCK
  • 5/3/2022 - 3 years ago
    21 - ABANDONMENT - FAILURE TO RESPOND OR LATE RESPONSE Type: ABN2
  • 5/3/2022 - 3 years ago
    22 - ABANDONMENT NOTICE MAILED - FAILURE TO RESPOND Type: MAB2
  • 5/3/2022 - 3 years ago
    23 - ABANDONMENT NOTICE E-MAILED - FAILURE TO RESPOND Type: MAB2
  • 5/9/2022 - 3 years ago
    24 - TEAS PETITION TO REVIVE RECEIVED Type: PROA
  • 5/9/2022 - 3 years ago
    25 - PETITION TO REVIVE-GRANTED Type: PETG
  • 5/9/2022 - 3 years ago
    26 - TEAS RESPONSE TO OFFICE ACTION RECEIVED Type: TROA
  • 5/10/2022 - 3 years ago
    27 - NOTICE OF REVIVAL - E-MAILED Type: NREV
  • 5/11/2022 - 3 years ago
    28 - ASSIGNED TO LIE Type: ALIE
  • 5/18/2022 - 3 years ago
    29 - CORRESPONDENCE RECEIVED IN LAW OFFICE Type: CRFA
  • 5/18/2022 - 3 years ago
    30 - TEAS/EMAIL CORRESPONDENCE ENTERED Type: TEME
  • 5/18/2022 - 3 years ago
    31 - SUSPENSION LETTER WRITTEN Type: CNSL
  • 5/18/2022 - 3 years ago
    32 - LETTER OF SUSPENSION E-MAILED Type: GNSL
  • 5/18/2022 - 3 years ago
    33 - NOTIFICATION OF LETTER OF SUSPENSION E-MAILED Type: GNS3
  • 10/28/2022 - 3 years ago
    34 - TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED Type: REAP
  • 10/28/2022 - 3 years ago
    35 - ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED Type: ARAA
  • 10/28/2022 - 3 years ago
    36 - TEAS CHANGE OF DOMESTIC REPRESENTATIVES ADDRESS Type: ECDR
  • 10/28/2022 - 3 years ago
    37 - TEAS CHANGE OF CORRESPONDENCE RECEIVED Type: TCCA
  • 11/15/2022 - 3 years ago
    38 - SUSPENSION INQUIRY WRITTEN Type: CNSI
  • 11/15/2022 - 3 years ago
    39 - INQUIRY TO SUSPENSION E-MAILED Type: GNSI
  • 11/15/2022 - 3 years ago
    40 - NOTIFICATION OF INQUIRY AS TO SUSPENSION E-MAILED Type: GNS2
  • 5/15/2023 - 2 years ago
    41 - TEAS RESPONSE TO SUSPENSION INQUIRY RECEIVED Type: ERSI
  • 1/30/2024 - a year ago
    42 - ASSIGNED TO LIE Type: ALIE
  • 1/30/2024 - a year ago
    43 - CORRESPONDENCE RECEIVED IN LAW OFFICE Type: CRFA
  • 1/30/2024 - a year ago
    44 - TEAS/EMAIL CORRESPONDENCE ENTERED Type: TEME
  • 2/2/2024 - a year ago
    45 - ASSIGNED TO EXAMINER Type: DOCK
  • 2/7/2024 - a year ago
    46 - SUSPENSION LETTER WRITTEN Type: CNSL
  • 2/7/2024 - a year ago
    47 - LETTER OF SUSPENSION E-MAILED Type: GNSL
  • 2/7/2024 - a year ago
    48 - NOTIFICATION OF LETTER OF SUSPENSION E-MAILED Type: GNS3
  • 12/27/2024 - 10 months ago
    50 - INQUIRY TO SUSPENSION E-MAILED Type: GNSI
  • 12/27/2024 - 10 months ago
    49 - SUSPENSION INQUIRY WRITTEN Type: CNSI
  • 12/27/2024 - 10 months ago
    51 - NOTIFICATION OF INQUIRY AS TO SUSPENSION E-MAILED Type: GNS2
  • 3/13/2025 - 8 months ago
    52 - TEAS RESPONSE TO SUSPENSION INQUIRY RECEIVED Type: ERSI
  • 3/14/2025 - 8 months ago
    53 - CORRESPONDENCE RECEIVED IN LAW OFFICE Type: CRFA
  • 3/14/2025 - 8 months ago
    54 - TEAS/EMAIL CORRESPONDENCE ENTERED Type: TEME
  • 3/14/2025 - 8 months ago
    55 - APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED Type: CHAN
  • 3/16/2025 - 8 months ago
    56 - SUSPENSION LETTER WRITTEN Type: CNSL
  • 3/16/2025 - 8 months ago
    57 - LETTER OF SUSPENSION E-MAILED Type: GNSL
  • 3/16/2025 - 8 months ago
    58 - NOTIFICATION OF LETTER OF SUSPENSION E-MAILED Type: GNS3